Skip to main content
NCBI home page
Frontiers in Neurology logoLink to Frontiers in Neurology
. 2022 Jul 15;13:887164. doi: 10.3389/fneur.2022.887164

A Systematic Review on Neurological Aspects of COVID-19: Exploring the Relationship Between COVID-19-Related Olfactory Dysfunction and Neuroinvasion

Sujata Purja 1,†, SuA Oh 1,†, EunYoung Kim 1,2,*,†
PMCID: PMC9334857  PMID: 35911902

Abstract

Objectives

To identify neurological aspects of Coronavirus disease 2019 (COVID-19) and to investigate COVID-19 infected patients with and without olfactory dysfunction in relation to polymerase chain reaction (PCR) assay results for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in the cerebrospinal fluid (CSF).

Methods

PubMed and EMBASE databases were searched until March 26, 2021, for observational studies with COVID-19 patients that had performed CSF PCR assay due to the neurologic symptom and reported anosmia status.

Results

Initially, 2,387 studies were identified;167 studies performed SARS-CoV-2 CSF PCR assay, of which our review comprised 45 observational studies that conducted CSF PCR assay for SARS-CoV-2 in 101 patients and reported anosmia status in 55 of 101 patients. Central and peripheral neurological manifestations observed in COVID-19 patients were diverse. The most common neurological diagnoses were Guillain-Barré syndrome (GBS) and its variants (24%), followed by encephalopathy (21%). The SARS-CoV-2 PCR assay was positive in only four CSF samples, of which two patients had olfactory dysfunction while the others did not.

Conclusions

The neurological spectrum of COVID-19 is diverse, and direct neuroinvasion of SARS-CoV-2 is rare. The neuroprotection against SARS-CoV-2 in COVID-19 patients with anosmia is controversial, as an equal number of patients with and without olfactory dysfunction had positive CSF PCR results for SARS-CoV-2 in our study, and further studies are required to provide more insight into this topic.

Keywords: COVID-19, SARS-CoV-2, anosmia, cerebrospinal fluid, neuroinvasion

Introduction

The olfactory nerve connects the nasal cavity to the central nervous system (CNS) and provides a neuroinvasive shortcut to respiratory neurotropic viruses (1). The detection of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in the olfactory nerve and CNS of patients with coronavirus disease 2019 (COVID-19) suggests that SARS-CoV-2 has neuroinvasive potential via the olfactory pathway (2). Although SARS-CoV-2 neuroinvasion is uncommon, CNS viral transmission poses a significant threat to life (3).

Previous animal studies have demonstrated that respiratory neurotropic viral invasion induces apoptosis of olfactory receptor neurons (ORNs), preventing the viral transmission to the olfactory bulb and the CNS (4, 5). Although the exact mechanism underlying COVID-19 related anosmia is unclear, human and animal studies have shown that anosmia is a consequence of a host defense mechanism against viral invasion involving the damage of olfactory epithelium might provide neuroprotection (2, 5–9). Furthermore, anosmia is frequently seen in milder forms of COVID-19 with a lower mortality rate (10, 11). Therefore, neuroprotection is anticipated in COVID-19 patients with anosmia.

Understanding the underlying mechanism and prognostic value of COVID-19-related anosmia will aid better patient management since olfactory dysfunction is often associated with several neurological disorders (12). This systematic review aimed to compile studies involving COVID-19 patients with neurological manifestations who have undergone polymerase chain reaction (PCR) testing for SARS-CoV-2 in cerebrospinal fluid (CSF) and reported the patient's anosmia status for identifying neurological aspects of COVID-19 and exploring the COVID-19 infected patients with or without anosmia in relation to their CSF PCR assay results.

Methods

Eligibility Criteria

The observational studies related to CSF analysis of COVID-19 patients with neurological symptoms were included. Target patients were COVID-19 patients diagnosed based on either positive SARS-CoV-2 PCR or serologic testing who had a neurological manifestation and have undergone SARS-CoV-2 CSF PCR testing to identify COVID-19-related neurological disorders. Studies that conducted CSF PCR assay for SARS-CoV-2 but did not report information on the status of anosmia were excluded. The study covered primary, retrievable scientific literature available in English. Collected data were each patient's sex and age distribution, SAR-CoV-2 CSF PCR assay, neurological presentation, treatment, and outcome. Therefore, studies that did not report these data properly were also excluded.

Search Strategy

We conducted a broad literature search of databases such as EMBASE and PubMed until March 26, 2021, following preferred reporting items for systematic reviews and meta-analysis (PRISMA) checklist (13) for studies that performed CSF PCR assay for SARS-CoV-2 in COVID-19 patients using population search terms “SARS-CoV-2” or “COVID-19” and intervention search terms “brain” or “cerebrospinal fluid” or “anosmia”.

Study Selection

Two independent authors screened studies based on the titles and abstracts. Any studies relevant to the CSF analysis of patients with COVID-19 were advanced to the second stage of the review. Full texts were reviewed using the eligibility criteria mentioned above in the second screening. Any disagreement between the authors was resolved by discussion.

Risk of Bias Assessment

The Joanna Briggs Institute (JBI) critical appraisal checklist was used to assess the risk of bias in each included study (14).

Data Extraction and Analysis

Two authors independently collected the data items included in the study design for each eligible study. For evaluating neurological aspects of COVID-19, individual patient data on neurological presentation, treatment, and outcomes were collected. The data items included individual's age and sex distribution, CSF PCR assay result, anosmia status, COVID-19-related neurological symptoms, neurological diagnosis, treatment, and outcomes. Each COVID-19 patient's data with neurological manifestations who had undergone CSF PCR testing for SARS-CoV-2 to identify COVID-19-related neurological disorders was summarized to characteristics, clinical presentation, SARS-CoV-2 PCR assay results, neurological diagnosis, treatment, and outcomes.

Results

Study Selection

In total, 2,387 studies were identified through a literature search after removing duplicates. After preliminary screening based on the titles and abstracts, a total of 379 studies related to CSF analysis of COVID-19 patients with neurological symptoms were included; among them, 167 studies (44%) that conducted PCR tests for SARS-CoV-2 in CSF were selected for full-text review. A total of 122 studies that conducted CSF PCR assay for SARS-CoV-2 but did not report information on the status of anosmia were excluded. Thus, only 45 articles that met the inclusion criteria were included in our study (15–59). A flow diagram of the study selection process is shown in Figure 1.

Figure 1.

Figure 1

Open in a new tab

PRISMA flowchart.

Risk of Bias

Overall, the risk of bias in the included studies was low except for three studies (15, 21, 57). The summary of JBI critical appraisal results for case reports and case series can be seen in Supplementary Tables 1, 2.

Participants and Characteristics of Studies

The total number of participants was 104, while the SARS-CoV-2 CSF PCR testing was performed on only 101 patients. Table 1 shows the characteristics of the 101 participants included in the review. More than 63.4% (64/101) were men. The mean age was 57 ± 16.37 years. The number of men and women infected with COVID-19 increased with age. COVID-19 infected patients of both sexes, predominantly in the 60–79 age group (Figure 2).

Table 1.

Characteristics of studies included in the review.

References Total case Age/sex SARS-CoV-2 diagnostic CSF PCR LOS Neurological diagnosis Treatment Outcome
Case report
Andriuta et al. (15) 2 NR/F NPS Neg Yes Encephalopathy NR NR
NR/M NS Neg NR Encephalopathy NR Unawaken
Assini et al. (16) 2 55/M OPS Neg Yes Polyradicoloneuritis Idrossichlorochine, arbidol, L/R, IVIG Non-fatal
60/M NPS Neg NR Polyradicoloneuritis HCQ, ART, Tocilizumab, IVIG Non-fatal
Atakla et al. (17) 1 41/M NPS Neg Yes GBS IVIG, AZ, chloroquine Non-fatal
Bigaut et al. (18) 2 43/M NPS Neg Yes GBS IVIG Non-fatal
70/F NPS Neg Yes GBS IVIG Non-fatal
Bodro et al. (19) 2 25/M NPS Neg No Encephalitis AC, antibiotics Non-fatal
49/M NPS Neg No Encephalitis AC, antibiotics Non-fatal
Canavero et al. (20) 2 25/F NPS Neg Yes Post-infectious demyelinating myelitis Steroid Non-fatal
69/M NPS Neg NR Encephalomyelitis CF, AC, L/R, HCQ, steroid, IVIG Non-fatal
Casez et al. (21) 1 96/F Serology Neg Yes Encephalitis NR NR
Cebrián et al. (22) 1 74/F NPS Pos No Headache NSAIDs, CF, HCQ, L/R Non-fatal
Chakraborty et al. (23) 1 59/F NPS, OPS Neg No Acute transverse myelitis Steroids and antipyretics Fatal
Chan et al. (24) 1 58/M OPS Neg No GBS IVIG Non-fatal
Chauffier et al. (25) 1 47/M NPS Neg No Encephalopathy No medical treatment Non-fatal
Chaumont et al. (26) 1 69/M BAL Neg Yes Meningoencephalitis AC, HCQ, AZ Non-fatal
Chow et al. (27) 1 60/M NPS Neg Yes Acute transverse myelitis Steroid Non-fatal
Civardi et al. (28) 1 72/F NPS Neg Yes GBS IVIG, HCQ, Doxycycline Non-fatal
Cohen et al. (29) 1 45/M NPS Neg Yes Parkinson's disease Steroid, biperiden Non-fatal
Corrêa et al. (30) 1 51/F NS Neg Yes Enecephalomyeloradiculitis Steroid, PE, azathioprine Non-fatal
De Gennaro et al. (31) 2 42/M NPS Neg No Cranial neuritis Remdesivir, sedatives, curare, IVIG Non-fatal
67/M NPS Neg No Cranial neuritis Antibiotics, anesthetic, noradrenalin, IVIG Non-fatal
Demirci Otluoglu et al. (32) 1 48/M CSF Pos Yes Encephalomyelitis HCQ, Favipiravir, P/T,levetiracetam, steroid, AC Non-fatal
Dijkstra et al. (33) 1 44/M NPS Neg Yes Myoclonic syndrome Steroid and IVIG Non-fatal
Fadakar et al. (34) 1 47/M NPS, OPS Pos No Cerebellitis L/R Non-fatal
Grimaldi et al. (35) 1 72/M NPS Neg No Encephalitis IVIG, steroid, benzodiazepines Non-fatal
Gutiérrez-Ortiz et al. (36) 2 50/M OPS Neg Yes Miller fisher syndrome IVIG Non-fatal
39/M OPS Neg NR PNC Acetaminophen Non-fatal
Helbok et al. (37) 1 68/M Serology Neg Yes GBS Steroid, IVIG, PE Non-fatal
Huber et al. (38) 1 21/F Serology Neg Yes Myasthenia gravis IVIG and pyridostigmine Non-fatal
Le Guennec et al. (39) 1 69/M TA Neg Yes Status epilepticus Levetiracetam and IVIG Non-fatal
Lim et al. (40) 1 55/F NPS Neg Yes Psychotic disorder Benzodiazepine, antipsychotic Non-fatal
Moore et al. (41) 1 28/M NPS Neg Yes Multiple sclerosis Steroid Non-fatal
Muccioli et al. (42) 1 47/F NPS Neg Yes Encephalopathy Tocilizumab Non-fatal
Naddaf et al. (43) 1 58/F Serology Neg No GBS HCQ, zinc, steroid, PE Non-fatal
Novi et al. (44) 1 64/F CSF Pos Yes ADEM Steroid with OPT, IVIG Non-fatal
Oguz-Akarsu et al. (45) 1 53/F NPS Neg No GBS PE, HCQ, AZ Non-fatal
Palao et al. (46) 1 29/F Serology Neg Yes Multiple sclerosis Steroid with OPT Non-fatal
Pascual-Goñi et al. (47) 2 60/F NPS Neg Yes Encephalopathy Thiamine, pyridoxine, HCQ, AZ Non-fatal
35/F NPS Neg NR Encephalopathy Thiamine and pyridoxine Non-fatal
Riva et al. (48) 1 NR/M Serology Neg Yes GBS IVIG Non-fatal
Umapathi et al. (49) 2 59/M NPS Neg No ADEM Low molecular weight heparin, IVIG Non-fatal
73/M NPS Neg NR Encephalopathy Interferon-beta 1b, L/R, steroid Fatal
Vandervorst et al. (50) 1 29/M NPS Neg Yes Encephalitis HCQ, nebivolol, amlodipine, antipsychotic, benzodiazepines Non-fatal
Zanin et al. (51) 1 54/F Pos; swab unclear Neg Yes Brain & spine demyelinating lesions ART, HCQ, antiepileptics, steroid Non-fatal
Zhou et al. (52) 1 26/M NS, OPS Neg No MOG-IgG-MD Steroid with OPT Non-fatal
Zoghi et al. (53) 1 21/M Serology Neg No Central demyelinating brain injury PE, antibiotics, AC Non-fatal
Case series
Cao et al. (54) 5 49/M NPS/TA Neg NR Encephalitis Steroid and PE Non-fatal
56/M NPS/TA Neg NR Encephalitis Steroid and PE Non-fatal
61/M NPS/TA Neg NR Encephalitis Steroid and PE Non-fatal
37/M NPS/TA Neg NR Encephalitis Steroid and PE Fatal
77/F NPS/TA Neg Yes Encephalitis Steroid and PE Fatal
Delorme et al. (55) 4 72/M NPS Neg Yes Encephalopathy IVIG Non-fatal
66/F NPS Neg NR Encephalopathy IVIG and steroid Non-fatal
60/F NPS Neg NR Encephalopathy Steroid, antidepressants Non-fatal
69/M NPS Neg Yes Encephalopathy Levetiracetam, sedative, IVIG, steroid Non-fatal
Manganotti et al. (56) 4 72/M NPS Neg Yes GBS HCQ, antivirals, steroid, tocilizumab Non-fatal
72/M NPS Neg Yes GBS HCQ, L/R, steroid Non-fatal
49/F NPS Neg Yes GBS HCQ, L/R, steroid Non-fatal
76/M NPS Neg Yes GBS HCQ, antivirals, steroid, tocilizumab, antibiotics, fluconazole Non-fatal
Neumann et al. (57) 30 81/M NPS Neg NR TIA NR NR
25/F NPS Neg NR CVST NR NR
48/F BAL Neg NR Encephalitis-HSV-1 NR NR
73/F NPS Neg NR Suspected post-stroke movement disorder NR NR
63/M BAL Neg NR Miller fisher syndrome NR NR
58/M BAL Neg NR Encephalopathy with Seizure NR NR
75/F NPS Neg Yes Encephalopathy DD limbic Encephalitis NR NR
66/M NPS, BAL Neg NR Intracranial hemorrhage NR NR
56/M OPS, BAL Neg NR Encephalopathy, CIP NR NR
41/F OPS Neg NR Osmotic demyelination syndrome NR NR
68/M BAL Neg NR Seizure NR NR
64/M OPS, BAL Neg NR Encephalopathy, CIP NR NR
57/M OPS, BAL Neg NR Status epilepticus NR NR
75/M OPS, BAL Neg NR Encephalopathy, CIP NR NR
47/M OPS, BAL Neg NR Encephalopathy, CIP NR NR
50/M OPS, BAL Neg NR Seizure NR NR
51/M OPS, BAL Neg NR Encephalopathy NR NR
65/F OPS Neg NR Encephalopathy NR NR
45/M OPS Neg NR Unclear headache NR NR
68/F OPS Neg NR Encephalopathy NR NR
81/M OPS, BAL Neg NR Encephalopathy NR NR
48/M OPS Neg Yes UVN NR NR
58/F OPS Neg NR UANP NR NR
80/M OPS Neg Yes Encephalopathy NR NR
70/M OPS, BAL Neg NR CIP, Ischemic stroke NR NR
76/F OPS, BAL Neg NR Prolonged coma NR NR
79/F OPS, BAL Neg NR GBS and encephalopathy NR NR
28/F OPS Neg NR Ischemic stroke NR NR
68/M OPS Neg NR Seizures NR NR
86/F OPS Neg NR GBS NR NR
Perrin et al. (58) 5 71/F NPS Neg NR Encephalopathy Levetiracetam and steroid Fatal
64/M NPS Neg NR Encephalopathy L/R, benzodiazepine, steroid, IVIG Non-fatal
53/F NPS Neg NR Encephalopathy HCQ Non-fatal
51/M NPS Neg NR Encephalopathy HCQ Non-fatal
67/M NPS Neg Yes Encephalopathy HCQ, steroids Non-fatal
Toscano et al. (59) 5 77/F NPS Neg NR GBS IVIG Non-fatal
23/M NPS Neg NR GBS IVIG Non-fatal
55/M NPS Neg NR GBS IVIG Non-fatal
76/M NPS Neg Yes GBS IVIG Non-fatal
61/M Serology Neg Yes GBS IVIG and PE Non-fatal
Open in a new tab

AC, acyclovir; ADEM, Acute disseminating encephalomyelitis; ART, antiretroviral therapy; AZ, azithromycin; BAL, Bronchoalveolar lavage; CF, ceftriaxone; CIP, critical illness polyneuropathy; CSF, cerebrospinal fluid; CVST, Cerebral venous sinus thrombosis; DD, differential diagnosis; GBS, Guillain-Barré syndrome; HCQ, hydroxychloroquine; HSV, herpes simplex virus; IVIG, intravenous immunoglobulin; LOS, loss of smell; L/R, lopinavir and ritonavir; MOG-IgG-MD, myelin oligodendrocyte glycoprotein- antibody-mediated disease; NPS, nasopharyngeal swab; NS, nasal swab; NSAIDs, Non-steroidal anti-inflammatory drug; OPS, oropharyngeal swab; OPT, oral prednisolone tapering; PCR, polymerase chain reaction; PE, plasma exchange; PNC, Polyneuritis cranialis; P/T, piperacillin and tazobactam; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; TA, tracheal aspirate; TIA, Transient ischemic attack; UVN, Unilateral Vestibular Neuritis.

NR denotes data not reported in the studies, F means female, M means male, Pos means positive, and Neg means negative.

Figure 2.

Figure 2

Open in a new tab

Age and sex distribution of COVID-19 patients who underwent CSF PCR assay for SARS-CoV-2. The number of men and women infected with COVID-19 who developed severe neurological manifestations and underwent CSF PCR assay for SARS-CoV-2 increased as the age of the individuals increased. The impact of COVID-19 was higher in patients aged 60-70 years old of both sexes. In addition, there were more COVID-19 infected men than COVID-19 infected women of all ages. COVID-19, coronavirus disease 2019; CSF, cerebrospinal fluid; PCR, polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2. NR denotes that the ages of two males and one female were not reported.

Neurological Aspects of COVID-19

Clinical Presentation

The neurological symptoms observed in COVID-19 individuals were diverse. The most common COVID-19-related neurological symptoms were smell disorder, taste disorder, headache, myalgia, altered consciousness, related paresis, and related cognitive and behavioral disturbances.

Neurological Diagnosis

The neurological diagnosis made after the neurological and radiological examination was localized to CNS (61.39%), peripheral nervous system (32.67%), or both (5.94%). In a study comprising 30 participants, six patients were diagnosed with two neurological disorders (57). The most common neurological diagnosis included Guillain-Barré syndrome and its variant (24%), followed by encephalopathy (21%) (Table 1).

Treatment and Outcomes

Information on the therapeutic management of COVID-19 was available for only 69 patients, including one patient who did not require medical treatment. In most cases, therapeutic management of COVID-19 patients involved combinational therapies. Common treatments included steroids administration (n = 32/69), intravenous immunoglobulin infusion (n = 28/69), hydroxychloroquine (n = 18/69), and plasma exchange (n = 11/69). Other medications used in the management of COVID-19 patients are shown in Table 1. The administration of medications resulted in neurological improvement in most patients. There were 63 non-fatal cases, five fatal cases, and one patient did not regain consciousness even after sedation was discontinued.

SARS-CoV-2 PCR Assay Results

Patients were confirmed to be COVID-19 positive when tested positive in PCR assay from nasopharyngeal swab or nasal swab (50/101), oropharyngeal swab (14/101), bronchoalveolar lavage (5/101), tracheal aspirate (1/101), or a combination of them (20/101). The PCR assay was positive in one study, but the swab used was not specified (51). Two patients were confirmed COVID-19 positive with the presence of SARS-CoV-2 in CSF (32, 44), and in eight patients with negative PCR test, COVID-19 infection was diagnosed with the presence of anti-SARS-CoV-2 in serum (Table 1) (21, 37, 38, 43, 46, 48, 53, 59).

CSF PCR assay for SARS-CoV-2 was positive for only four (3.96%) patients (22, 32, 34, 44) and negative in 97 (96.04%) patients (15–21, 23–31, 33, 35–43, 45–59). Of the 101 patients, information on the status of anosmia was available in 55 patients (51 patients had negative CSF PCR results, while four had positive CSF PCR results). Out of 51 patients with negative CSF PCR results, 38 had smell disorder, while 13 had no nasal symptoms. Meanwhile, two of the four patients with positive CSF PCR results for SARS-CoV-2 had olfactory dysfunction, while the other two did not (Table 1).

Discussion

This systematic review identified studies that performed CSF PCR assay for SARS-CoV-2 in COVID-19 positive patients and reported anosmia status to identify the common neurological manifestations associated with COVID-19 and to analyze the interrelation between CSF PCR results and anosmia. The neurological manifestations of COVID-19 are diverse. There was an equal number of patients with and without olfactory disorders who had positive CSF PCR results for SARS-CoV-2.

COVID-19 can trigger other autoimmune neurological complications such as neuromyelitis optica spectrum disorders or multiple sclerosis (30, 41, 46), which should be identified and treated promptly (44). In addition, COVID-19 patients with olfactory disorders and other severe neurological symptoms should be examined for possible neurodegenerative disease when suspected of having one (29).

In our study, ~4% of the participants had positive CSF PCR assay for SARS-CoV-2, similar to the finding of one study, which showed positive results in 6% of the participants, indicating SARS-CoV-2 neuroinvasion is a rare occurrence (3). However, negative CSF PCR results for SARS-CoV-2 may be due to delayed immune-mediated neurological damage after viral clearance (51, 53). Furthermore, the sensitivity decreases if samples are tested after a long period of symptom onset, giving negative results (43, 58). In addition, according to our review, only 44% of the published articles on CSF studies performed CSF PCR assay for SARS-CoV-2 in COVID-19 infected patients who experienced neurological symptoms. Therefore, despite the procedural and logistical complexity, the authors suggest an early collection of CSF samples, performing CSF PCR assay for SARS-CoV-2, detecting anti-neuronal autoantibodies, and using 18 F-fluorodeoxyglucose positron emission tomography in suspected cases could aid in the diagnosis and management of the patients, notably in magnetic resonance imaging negative cases (35, 51). Although the additional financial concern associated with the CSF PCR assay cannot be avoided, there were cases of testing positive in CSF PCR assay despite being negative in a nasal PCR or rapid COVID-19 test (32, 44). In addition, cost-effective studies in other neurotropic viruses have shown that the CSF PCR assay is cost-effective; similar studies in COVID-19 are required (60). Furthermore, a negative CSF PCR assay does not rule out the presence of the virus in the CNS; therefore, further studies of SARS-CoV-2 antibodies are required (57). Moreover, a recent study has shown that SARS-CoV-2 retrograde neuroinvasion via the olfactory route causes neuroinflammation (9). The detection of SARS-CoV-2 in the olfactory epithelium and various radiological findings in patients with COVID-19 suggests that despite the rarity of SARS-CoV-2 neuroinvasion via the olfactory system, it should not be overlooked (9, 21, 39, 61).

Similar to other respiratory neurotropic viruses, the direct neuroinvasion of SARS-CoV-2 in COVID-19 patients could occur mainly in two ways: damage to the olfactory epithelium or diffusion through the olfactory ensheathing cell (OEC) (1, 2) (Figure 3). Although ORNs of humans do not express SARS-CoV-2 entry proteins, factors other than angiotensin-converting enzyme-2 may be involved in a viral entry, such as neurolipin-1, which is highly expressed in ORNs (62–64) or SARS-CoV-2 can have non-neuronal mechanism (6, 9, 63). The neuronal and non-neuronal damage of the olfactory epithelium are responsible for the mechanism of loss of smell observed in COVID-19 patients (6, 7, 9). Nevertheless, viruses that are rapidly transported to the olfactory bulb before being affected by ORN apoptotic actions may invade the CNS (5).

Figure 3.

Figure 3

Open in a new tab

Possible mechanisms of neuroinvasion of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) via the olfactory pathway. SARS-CoV-2 can enter the central nervous system (CNS) through the olfactory system in one of two ways: directly through the cerebrospinal fluid (CSF) by crossing the channels created by olfactory ensheathing cells (OECs) (purple straight line) or through olfactory receptor neurons (ORNs). Since ORNs lack angiotensin-converting enzyme-2 (ACE-2), viruses are hypothesized to be transferred from sustentacular (SUS) cells, which contain ACE-2, either directly to mature ORNs (mORNs) or to stem cells (also containing ACE-2), which can then transfer the virus to immature ORNs (iORNs) during ORN regeneration process, where infected iORNs could grow into infected mORNs. The pink dotted line represents the hypotheses. Viruses can directly enter the CNS from ORN through ACE-2-independent mechanisms (green straight line) using factors such as neurolipin-1. The blue straight line represents the regeneration of ORNs and SUS cells from stem cells.

In addition, viruses as small as 100nm can also diffuse via the channels formed by OEC gaining direct access to the CSF (1, 65). The size of SARS-CoV-2 ranges from 60 to 140 nm (66). Additionally, direct infection of the OEC can release viruses into these channels and subsequently transport the virus to the olfactory bulb (1). Thus, SARS-CoV-2 with a smaller size can utilize this mode of viral transmission.

Studies analyzing the olfactory mucosa of COVID-19 patients with and without anosmia are required to acknowledge that apoptosis of ORNs is the cause of COVID-19-related anosmia. Future studies with a larger sample size involving nasal brush sampling method and CSF PCR assay can be performed on COVID-19 patients to determine whether apoptosis of ORNs could provide neuroprotection in COVID-19 patients with anosmia (9).

This study has several limitations. Olfactory mucosa biopsy is required to effectively analyze the association between apoptosis of ORNs with anosmia and neuroprotection. However, few studies were included in this analysis. Because the biopsy is an invasive procedure, it is rarely done in patients with COVID-19 only for research purposes (9), unlike animal studies. Additionally, studies that determine whether apoptosis of ORNs occurs in COVID-19 patients experiencing anosmia and SARS-CoV-2 CSF PCR assays are not available. For these reasons, the study design for analyzing the hypothesis was only feasible with observational studies. Though the risk of bias assessment showed an overall low risk, fundamental bias from the study design cannot be fully excluded. The findings from this review are not directly comparable with the results from other neurotropic viruses till these unanswered issues are solved. The number of patients with positive CSF PCR results did not differ by anosmia status, which may be related to the limited sample size and non-standard CSF PCR assay procedures. The CSF PCR assay is not commonly performed in COVID-19 patients with neurological manifestation. In this study, among COVID-19 patients with neurological manifestation, only 44% of patients underwent PCR assay for SARS-CoV-2 in the CSF to identify COVID-19 related neurological disorders. Though anosmia is common in COVID-19 patients, underreporting issues cannot be ignored, and because of limitation to our methodology, the neurological manifestations observed in individuals with COVID-19 cannot be generalized. Similarly, the possibility of an indirect mechanism of neuroinvasion of SARS-CoV-2 should not be overlooked. We could not investigate the neurological aspects of different strains of SARS-CoV-2 in COVID-19 infected patients and geographical and temporal relationships, particularly those concerning olfactory alteration, because information about the SARS-CoV-2 strain along with geographical and temporal information was not available in the included studies. Future studies with proper sample sizes involving definitive methods such as the nasal mucosa sampling method could provide a clear answer to the association between apoptosis of ORNs with anosmia and neuroprotection.

Conclusion

The neurological spectrum of COVID-19 is wide. Direct neuroinvasion of SARS-CoV-2 via the olfactory route is uncommon. Although previous experimental models of respiratory neurotropic viruses have demonstrated that apoptosis of the olfactory nerve blocks its neuroinvasive ability, this remains controversial in the case of SARS-CoV-2, since at present, human evidence is too scare limiting any conclusion to be drawn about the protection role of virus' olfactory mucosa invasion toward CNS invasion. More research with definitive methods is required to study the neuroprotective potential of ORN apoptosis in COVID-19 patients.

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

Author Contributions

EK had full access to all the data in the study and took responsibility for the integrity of the data and the accuracy of the data analysis. SP and EK: conceptualization, writing original draft, and formal analysis. SP, SO, and EK: data acquisition and writing review and editing. EK: funding and supervision. All authors contributed to the article and approved the submitted version.

Funding

This work was funded by a grant from the Korean government, South Korea (Ministry of Science and ICT, MICT; NRF-2021R1F1A1062044) and by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, South Korea (Grant Number 2021R1A6A1A03044296). The funder had no role in the trial design, data collection, data interpretation, or report preparation.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2022.887164/full#supplementary-material

Click here for additional data file. (38KB, docx)

References

  • 1.Van Riel D, Verdijk R, Kuiken T. The olfactory nerve: a shortcut for influenza other viral diseases into the central nervous system. J Pathol. (2015) 235:277–87. 10.1002/path.4461 [DOI] [PubMed] [Google Scholar]
  • 2.Meinhardt J, Radke J, Dittmayer C, Franz J, Thomas C, Mothes R, et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat. Neurosci. (2021) 24:168–175. 10.1101/2020.06.04.135012 [DOI] [PubMed] [Google Scholar]
  • 3.Lewis A, Frontera J, Placantonakis DG, Lighter J, Galetta S, Balcer L, et al. Cerebrospinal fluid in COVID-19: a systematic review of the literature. J Neurol Sci. (2021) 421:117316. 10.1016/j.jns.2021.117316 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Mori I, Goshima F, Imai Y, Kohsaka S, Sugiyama T, Yoshida T, et al. Olfactory receptor neurons prevent dissemination of neurovirulent influenza A virus into the brain by undergoing virus-induced apoptosis. J Gen Virol. (2002) 83:2109–2116. 10.1099/0022-1317-83-9-2109 [DOI] [PubMed] [Google Scholar]
  • 5.Mori I, Nishiyama Y, Yokochi T, Kimura Y. Virus-induced neuronal apoptosis as pathological and protective responses of the host. Rev Med Virol. (2004) 14:209–16. 10.1002/rmv.426 [DOI] [PubMed] [Google Scholar]
  • 6.Butowt R. and von Bartheld CS, Anosmia in COVID-19: underlying mechanisms and assessment of an olfactory route to brain infection. Neuroscientist. (2020) 2020:1073858420956905. 10.1177/1073858420956905 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Bryche B, St Albin A, Murri S, Lacôte S, Pulido C, Ar Gouilh M, et al. Massive transient damage of the olfactory epithelium associated with infection of sustentacular cells by SARS-CoV-2 in golden Syrian hamsters. Brain Behav Immun. (2020) 89:579–86. 10.1016/j.bbi.2020.06.032 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Le Bon SD, Horoi M. Is anosmia the price to pay in an immune-induced scorched-earth policy against COVID-19? Med Hypotheses. (2020) 143:109881. 10.1016/j.mehy.2020.109881 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.de Melo GD, Lazarini F, Levallois S, Hautefort C, Michel V, Larrous F, et al. COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters. Sci Transl Med. (2021) 13:eabf8396. 10.1126/scitranslmed.abf8396 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Talavera B, García-Azorín D, Martínez-Pías E, Trigo J, Hernández-Pérez I, Valle-Peñacoba G, et al. Anosmia is associated with lower in-hospital mortality in COVID-19. J Neurol Sci. (2020) 419:117163. 10.1016/j.jns.2020.117163 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Purja S, Shin H, Lee JY, Kim E. Is loss of smell an early predictor of COVID-19 severity: a systematic review and meta-analysis. Arch Pharm Res. (2021) 44:725–40. 10.1007/s12272-021-01344-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Ciurleo R, De Salvo S, Bonanno L, Marino S, Bramanti P, Caminiti F. Parosmia and neurological disorders: a neglected association. Front Neurol. (2020) 11:543275. 10.3389/fneur.2020.543275 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. (2021) 372:n71. 10.1136/bmj.n71 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, et al. Chapter 7: systematic reviews of etiology and risk. in JBI Manual for Evidence Synthesis JBI, editors Aromataris E, Munn Z (2020). Available online at: https://synthesismanual.jbi.global (accessed October 21, 2021).
  • 15.Andriuta D, Roger PA, Thibault W, Toublanc B, Sauzay C, Castelain S, et al. COVID-19 encephalopathy: detection of antibodies against SARS-CoV-2 in CSF. J Neurol. (2020) 267:2810–1. 10.1007/s00415-020-09975-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Assini A, Benedetti L, Di Maio S, Schirinzi E, Del Sette M. New clinical manifestation of COVID-19 related Guillain-Barrè syndrome highly responsive to intravenous immunoglobulins: two Italian cases. Neurol Sci. (2020) 41:1657–8. 10.1007/s10072-020-04484-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Atakla HG, Noudohounsi M, Sacca H, Tassiou NRA, Noudohounsi WC, Houinato DS. Acute Guillain-Barré polyradiculoneuritis indicative of COVID-19 infection: a case report. Pan Afr Med J. (2020) 35:150. 10.11604/pamj.supp.2020.35.2.25745 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Bigaut K, Mallaret M, Baloglu S, Nemoz B, Morand P, Baicry F, et al. Guillain-Barré syndrome related to SARS-CoV-2 infection. Neurol Neuroimmunol Neuroinflamm. (2020) 7:e785. 10.1212/NXI.0000000000000785 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Bodro M, Compta Y, Llansó L, Esteller D, Doncel-Moriano A, Mesa A, et al. Increased CSF levels of IL-1β, IL-6, and ACE in SARS-CoV-2-associated encephalitis. Neurol Neuroimmunol Neuroinflamm. (2020) 7:e821. 10.1212/NXI.0000000000000821 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Canavero I, Valentino F, Colombo E, Franciotta D, Ferrandi D, Mussa M, et al. Acute myelopathies associated to SARS-CoV-2 infection: viral or immune-mediated damage? Travel Med Infect Dis. (2021) 40:102000. 10.1016/j.tmaid.2021.102000 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Casez O, Willaume G, Grand S, Nemoz B, Lupo J, Kahane P, et al. Teaching neuroimages: SARS-CoV-2–related encephalitis. MRI Pattern Olfact Tract Involvement Neurol. (2021) 96:e645–6. 10.1212/WNL.0000000000011150 [DOI] [PubMed] [Google Scholar]
  • 22.Cebrián J, Gonzalez-Martinez A, García-Blanco MJ, Celdrán-Vivancos D, Palacios EL, Reig-Roselló G, et al. Headache and impaired consciousness level associated with SARS-CoV-2 in CSF: a case report. Neurology. (2020) 95:266–8. 10.1212/WNL.0000000000010213 [DOI] [PubMed] [Google Scholar]
  • 23.Chakraborty U, Chandra A, Ray AK, Biswas P. COVID-19-associated acute transverse myelitis: a rare entity. BMJ Case Rep. (2020) 13:e238668. 10.1136/bcr-2020-238668 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Chan JL, Ebadi H, Sarna JR. Guillain-Barré Syndrome with facial diplegia related to SARS-CoV-2 infection. Can J Neurol Sci. (2020) 47:852–4. 10.1017/cjn.2020.106 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Chauffier J, Poey N, Husain M, de Broucker T, Khalil A, Lariven S, et al. First case of mild encephalopathy with reversible splenial lesion in SARS-CoV-2 infection. Infect Dis Now. (2021) 51:99–101. 10.1016/j.medmal.2020.09.018 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Chaumont H, Etienne P, Roze E, Couratier C, Roger PM, Lannuzel A. Acute meningoencephalitis in a patient with COVID-19. Rev Neurol. (2020) 176:519–21. 10.1016/j.neurol.2020.04.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Chow CCN, Magnussen J, Ip J, Su Y. Acute transverse myelitis in COVID-19 infection. BMJ Case Rep. (2020) 13:e236720. 10.1136/bcr-2020-236720 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Civardi C, Collini A, Geda DJ, Geda C. Antiganglioside antibodies in Guillain-Barré syndrome associated with SARS-CoV-2 infection. J Neurol Neurosurg Psychiatry. (2020) 91:1361–2. 10.1136/jnnp-2020-324279 [DOI] [PubMed] [Google Scholar]
  • 29.Cohen ME, Eichel R, Steiner-Birmanns B, Janah A, Ioshpa M, Bar-Shalom R, et al. A case of probable Parkinson's disease after SARS-CoV-2 infection. Lancet Neurol. (2020) 19:804–5. 10.1016/S1474-4422(20)30305-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Corrêa DG, de Souza Lima FC, da Cruz Bezerra D, Coutinho AC, Hygino da. Cruz LC. COVID-19 associated with encephalomyeloradiculitis and positive anti-aquaporin-4 antibodies: cause or coincidence? Mult Scler. (2021) 27:973–6. 10.1177/1352458520949988 [DOI] [PubMed] [Google Scholar]
  • 31.De Gennaro R, Gastaldo E, Tamborino C, Baraldo M, Casula N, Pedrali M, et al. Selective cranial multineuritis in severe COVID-19 pneumonia: two cases and literature review. Neurol Sci. (2021) 2021:1–6. 10.1007/s10072-021-05087-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Demirci Otluoglu G, Yener U, Demir MK, Yilmaz B. Encephalomyelitis associated with Covid-19 infection: case report. Br J Neurosurg. (2020) 2020:1–3. 10.1080/02688697.2020.1787342 [DOI] [PubMed] [Google Scholar]
  • 33.Dijkstra F, Van den Bossche T, Willekens B, Cras P, Crosiers D. Myoclonus and cerebellar ataxia following Coronavirus Disease (2019). (COVID-19) Mov Disord Clin Pract. (2020) 7:974–6. 10.1002/mdc3.13049 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Fadakar N, Ghaemmaghami S, Masoompour SM, Shirazi Yeganeh B, Akbari A, Hooshmandi S, et al. A first case of acute cerebellitis associated with coronavirus disease (COVID-19): a case report and literature review. Cerebellum. (2020) 19:911–4. 10.1007/s12311-020-01177-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Grimaldi S, Lagarde S, Harlé JR, Boucraut J, Guedj E. Autoimmune Encephalitis Concomitant with SARS-CoV-2 infection: insight from (18)F-FDG PET imaging and neuronal autoantibodies. J Nucl Med. (2020) 61:1726–9. 10.2967/jnumed.120.249292 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Gutiérrez-Ortiz C, Méndez-Guerrero A, Rodrigo-Rey S, San Pedro-Murillo E, Bermejo-Guerrero L, Gordo-Mañas R, et al. Miller fisher syndrome and polyneuritis cranialis in COVID-19. Neurology. (2020) 95:e601–5. 10.1212/WNL.0000000000009619 [DOI] [PubMed] [Google Scholar]
  • 37.Helbok R, Beer R, Löscher W, Boesch S, Reindl M, Hornung R, et al. Guillain-Barré syndrome in a patient with antibodies against SARS-CoV-2. Eur J Neurol. (2020) 27:1754–6. 10.1111/ene.14388 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Huber M, Rogozinski S, Puppe W, Framme C, Höglinger G, Hufendiek K, et al. Postinfectious onset of myasthenia gravis in a COVID-19 patient. Front Neurol. (2020) 11:576153. 10.3389/fneur.2020.576153 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Le Guennec L, Devianne J, Jalin L, Cao A, Galanaud D, Navarro V, et al. Orbitofrontal involvement in a neuroCOVID-19 patient. Epilepsia. (2020) 61:e90–4. 10.1111/epi.16612 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Lim ST, Janaway B, Costello H, Trip A, Price G. Persistent psychotic symptoms following COVID-19 infection. BJPsych Open. (2020) 6:e105. 10.1192/bjo.2020.76 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Moore L Ghannam M Manousakis G A. first presentation of multiple sclerosis with concurrent COVID-19 infection. eNeurologicalSci. (2021) 22:100299. 10.1016/j.ensci.2020.100299 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Muccioli L, Pensato U, Cani I, Guerra L, Provini F, Bordin G, et al. COVID-19-related encephalopathy presenting with aphasia resolving following tocilizumab treatment. J Neuroimmunol. (2020) 349:577400. 10.1016/j.jneuroim.2020.577400 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Naddaf E, Laughlin RS, Klein CJ, Toledano M, Theel ES, Binnicker MJ, et al. Guillain-barré syndrome in a patient with evidence of Recent SARS-CoV-2 Infection. Mayo Clin Proc. (2020) 95:1799–801. 10.1016/j.mayocp.2020.05.029 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Novi G, Rossi T, Pedemonte E, Saitta L, Rolla C, Roccatagliata L, et al. Acute disseminated encephalomyelitis after SARS-CoV-2 infection. Neurol Neuroimmunol Neuroinflamm. (2020) 7:e797. 10.1212/NXI.0000000000000797 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Oguz-Akarsu E, Ozpar R, Mirzayev H, Acet-Ozturk NA, Hakyemez B, Ediger D, et al. Guillain-Barré syndrome in a patient with minimal symptoms of COVID-19 infection. Muscle Nerve. (2020) 62:e54–7. 10.1002/mus.26992 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Palao M, Fernández-Díaz E, Gracia-Gil J, Romero-Sánchez CM, Díaz-Maroto I, Segura T. Multiple sclerosis following SARS-CoV-2 infection. Mult Scler Relat Disord. (2020) 45:102377. 10.1016/j.msard.2020.102377 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Pascual-Goñi E, Fortea J, Martínez-Domeño A, Rabella N, Tecame M, Gómez-Oliva C, et al. COVID-19-associated ophthalmoparesis and hypothalamic involvement. Neurol Neuroimmunol Neuroinflamm. (2020) 7:e823. 10.1212/NXI.0000000000000823 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Riva N, Russo T, Falzone YM, Strollo M, Amadio S, Del Carro U, et al. Post-infectious Guillain-Barré syndrome related to SARS-CoV-2 infection: a case report. J Neurol. (2020) 267:2492–4. 10.1007/s00415-020-09907-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Umapathi T, Quek WMJ, Yen JM, Khin HSW, Mah YY, Chan CYJ, et al. Encephalopathy in COVID-19 patients; viral, parainfectious, or both? eNeurologicalSci. (2020) 21:100275. 10.1016/j.ensci.2020.100275 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Vandervorst F, Guldolf K, Peeters I, Vanderhasselt T, Michiels K, Berends KJ, et al. Encephalitis associated with the SARS-CoV-2 virus: a case report. Interdiscip Neurosurg. (2020) 22:100821. 10.1016/j.inat.2020.100821 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Zanin L, Saraceno G, Panciani PP, Renisi G, Signorini L, Migliorati K, et al. SARS-CoV-2 can induce brain and spine demyelinating lesions. Acta Neurochir (Wien). (2020) 162:1491–4. 10.1007/s00701-020-04374-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Zhou S, Jones-Lopez EC, Soneji DJ, Azevedo CJ, Patel VR. Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis and myelitis in COVID-19. J Neuroophthalmol. (2020) 40:398–402. 10.1097/WNO.0000000000001049 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Zoghi A Ramezani M Roozbeh M Darazam IA Sahraian MA A. case of possible atypical demyelinating event of the central nervous system following COVID-19. Mult Scler Relat Disord. (2020) 44:102324. 10.1016/j.msard.2020.102324 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Cao A, Rohaut B, Le Guennec L, Saheb S, Marois C, Altmayer V, et al. Severe COVID-19-related encephalitis can respond to immunotherapy. Brain. (2020) 143:e102–e102. 10.1093/brain/awaa337 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Delorme C, Paccoud O, Kas A, Hesters A, Bombois S, Shambrook P, et al. COVID-19-related encephalopathy: a case series with brain FDG-positron-emission tomography/computed tomography findings. Eur J Neurol. (2020) 27:2651–7. 10.1111/ene.14478 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Manganotti P, Bellavita G, D'Acunto L, Tommasini V, Fabris M, Sartori A, et al. Clinical neurophysiology and cerebrospinal liquor analysis to detect Guillain-Barré syndrome and polyneuritis cranialis in COVID-19 patients: a case series. J Med Virol. (2021) 93:766–74. 10.1002/jmv.26289 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Neumann B, Schmidbauer ML, Dimitriadis K, Otto S, Knier B, Niesen WD, et al. Cerebrospinal fluid findings in COVID-19 patients with neurological symptoms. J Neurol Sci. (2020) 418:117090. 10.1016/j.jns.2020.117090 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Perrin P, Collongues N, Baloglu S, Bedo D, Bassand X, Lavaux T, et al. Cytokine release syndrome-associated encephalopathy in patients with COVID-19. Eur J Neurol. (2021) 28:248–58. 10.1111/ene.14491 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, et al. Guillain-Barré syndrome associated with SARS-CoV-2. N Engl J Med. (2020) 382:2574–6. 10.1056/NEJMc2009191 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Hauser RG, Campbell SM, Brandt CA, Wang S. Cost-effectiveness study of criteria for screening cerebrospinal fluid to determine the need for herpes simplex virus PCR testing. J Clin Microbiol. (2017) 55:1566–75. 10.1128/JCM.00119-17 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Guedj E, Million M, Dudouet P, Tissot-Dupont H, Bregeon F, Cammilleri S, et al. (18)F-FDG brain PET hypometabolism in post-SARS-CoV-2 infection: substrate for persistent/delayed disorders? Eur J Nucl Med Mol Imaging. (2021) 48:592–5. 10.1007/s00259-020-04973-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Daly JL, Simonetti B, Klein K, Chen KE, Williamson MK, Antón-Plágaro C, et al. Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science. (2020) 370:861–5. 10.1126/science.abd3072 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Brann DH, Tsukahara T, Weinreb C, Lipovsek M, Van den Berge K, Gong B, et al. Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. Sci Adv. (2020) 6:eabc5801. 10.1126/sciadv.abc5801 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Cantuti-Castelvetri L, Ojha R, Pedro LD, Djannatian M, Franz J, Kuivanen S, et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science. (2020) 370:856–60. 10.1126/science.abd2985 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Oberdörster G, Sharp Z, Atudorei V, Elder A, Gelein R, Kreyling W, et al. Translocation of inhaled ultrafine particles to the brain. Inhal Toxicol. (2004) 16:437–45. 10.1080/08958370490439597 [DOI] [PubMed] [Google Scholar]
  • 66.Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from patients with pneumonia in China. N Engl J Med. (2020) 382:727–733. 10.1056/NEJMoa2001017 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Click here for additional data file. (38KB, docx)

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

Articles from Frontiers in Neurology are provided here courtesy of Frontiers Media SA

RESOURCES